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ABSTRACT 
 Transcatheter mitral valve replacement (TMVR) is being developed to become a 
substitute therapy for surgery in prohibitive or high surgical risk patients to treat severe 
mitral regurgitation. A limited number of TMVR systems are under clinical evaluation. 
However, transcatheter mitral valve (TMV) long-term durability and hemodynamic 
performance is not known. TMV durability and hemodynamics must match with that of 
surgical bioprostheses for potential commercialization of TMVR. Experimental and 
computational approaches were used to find the leaflets’ three-dimensional anisotropic 
mechanical properties in a transcatheter Edwards SAPIEN 3 valve and a surgical 
Carpentier-Edwards PERIMOUNT Magna mitral valve and finite element (FE) 
simulations were conducted to obtain the stress distribution on both valves. Moreover, to 
visualize the flow field within the left heart, steady-state computational fluid dynamics 
(CFD) simulations were run. The FE simulations demonstrated that in a cardiac cycle, at 
peak systole, the highest stress value in the two bioprostheses was 4.75 and 16 MPa for the 
surgical and transcatheter heart valve, respectively. After studying the leaflet stress 
distributions and flow field, long-term durability may potentially be different between the 
two models. The results of CFD simulations could potentially show that TMVs with supra-
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CHAPTER ONE: INTRODUCTION 
 
Mitral regurgitation (MR) is a widespread valvular heart disease in the western 
world. In the United States alone, it is estimated that the prevalence of moderate and severe 
MR is between 2 to 2.5 million at present. This number is predicted to reach 5 million cases 
by 2030 (1). MR presence rises with age, resulting in a sharp increase in the number of 
patients in need of hospital care and intervention over the next decades (2). The 
consequences of untreated MR include progressive left ventricular (LV) dilation, 
myocardial dysfunction, and cardiac failure, resulting in considerable morbidity and 
mortality, and creating a great economic burden (3). MR is categorized into two types 
based on etiology: degenerative (primary) and functional (secondary).  
Primary MR is defined as any abnormalities in the mitral valve apparatus that cause 
MR. The Carpentier classification is used to differentiate etiologies in MR (Figure 1). In 
Carpentier type I, MR is caused by a perforation in the leaflets or congenital clefts but the 
leaflets have normal size and motion. Flail leaflets or excessive leaflet motion with 
prolapse are categorized as Carpentier type II MR. Restricted leaflet motion during diastole 
is witnessed in Carpentier type IIIa MR. Contrary to primary MR, secondary MR has 
nothing to do with the mitral valve itself; a diseased left atrium or ventricle is causing the 
MR. Ischemic and nonischemic cardiomyopathy are two main types of ventricular disease 
that lead to MR. Due to nonischemic cardiomyopathy, annular dilation and loss of annular
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contraction occurs, resulting in an increase of the effective regurgitation orifice (ERO) and 
MR. This is classified as Carpentier type I MR as the leaflets and their motion are normal, 
but the dilated annulus causes malcoaptation of the leaflets. Another Carpentier type I form 
of functional MR is the annular dilation secondary to severe left atrial enlargement. 
Ischemic cardiomyopathy however, results in Carpentier type IIIb (restricted leaflet motion 
during systole) MR as it introduces regional inferior ventricular wall motion abnormalities 
which in turn leads to tethered posterior leaflets and a posterior-oriented MR (2). 
Figure 1-Classification of the etiology of MR with the Carpentier classification. Reprinted with 
permission from (2).  
 
Currently, in symptomatic patients that present with chronic severe primary MR 
and left ventricular ejection fraction (LVEF) of greater than 30%, mitral valve surgery is 
recommended and may be considered with LVEF less than or equal to 30%. For 
asymptomatic patients with chronic severe primary MR, mitral valve surgery is 
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recommended when patient is presented with left ventricle (LV) dysfunction and is 
reasonable with preserved LV function. The treatment plan for chronic secondary MR is 
harder to define as MR is the aftermath of the main disease, therefore just restoring the 
mitral valve’s capability is not curative. So in patients with chronic severe secondary MR, 
it is only deemed reasonable to do mitral valve surgery when patients are undergoing 
coronary artery bypass grafting (CABG) or aortic valve replacement (AVR) as well (4). In 
surgical MR treatment, repair and replacement are two available options although repair is 
generally favored over replacement (5)(6)(7).Surgical repair has led to favorable outcomes 
for the following diseases: annular dilation, degenerative mitral valve disease, leaflet 
perforation in endocarditis, chordal rupture, and ischemic papillary muscle dysfunction. 
Conversely, in elderly patients with rheumatic heart disease and calcified valves, or severe 
thickening of sub-valvular apparatus, outcomes are less favorable and surgical mitral 
replacement is the opted treatment plan (8). 
The advantages of surgical repair over replacement for degenerative mitral valve 
disease have been confirmed by numerous studies and include: higher early and late 
survival rates, better preservation of left ventricular function, and elimination of 
complications related to a prosthetic valve replacement such as thromboembolism, 
anticoagulation medication and endocarditis (7). In terms of durability, retrospective data 
shows valve repair is as durable or even more durable than replacement, keeping in mind 
that standard comparisons are with durability of a mechanical valve replacement (6). A 
recent 20-year outcome study also concluded that in degenerative cases with flail leaflets, 
MV repair has lower operative mortality, superior long-term survival, and less valve-
related complications compared with MV replacement. The study mentions changes in 
4 
 
surgical method for repair overtime but overall, any surgical method was complemented 
with a type of annuloplasty (5). It should be noted that a successful durable mitral repair is 
highly dependent on surgeon experience and is technically more complex than replacement 
(8). 
For functional MR (FMR), the benefits of surgical repair over replacement are not 
as clear. In ischemic mitral regurgitation (IMR) cases, a systematic review concluded that 
literature shows repair might be result in better surgical mortality and long-term survival 
in comparison with replacement, but also expressed significant uncertainty in the 
conclusion due to the heterogeneity of the available studies (6). A prevalent repair option 
for functional MR cases is mitral annuloplasty (MAP); studies suggest low postoperative 
mortality, improved heart failure symptoms, positive changes in ventricle size and ejection 
fraction with good outcomes in the intermediate time frame (9). Commonly, undersized 
mitral annuloplasty is used as a simple and reproducible approach for chronic IMR patients 
with the justification that undersizing the mitral annulus ameliorates regurgitation through 
improving coaptation of the leaflets (10). However, five-year survival after annuloplasty 
in FMR patients is at the unsatisfactory rate of 50% (11) and recurrent MR of moderate or 
worse level was reported in 28% of patients at 6 months post-op (10). The efficacy of MAP 
in comparison with mitral valve replacement (MVR) for functional MR patients was 
investigated, concluding that subvalvular apparatus sparing MVR is a safe substitute for 
MAP which leads to noticeable reduction of MR severity and LV size. The study suggested 
that for patients with multiple comorbidities, severe tethering and complicated 
regurgitation jets, subvalvular apparatus sparing MVR should be considered (11). 
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However, most severe MR cases do not get referred for surgery due to the high 
risks associated with the patients’ advanced age and various comorbidities, and the efficacy 
of valve surgery for secondary MR with LV dysfunction is still under question (3). In order 
to respond to the unmet clinical need of these MR cases, transcatheter mitral valve 
interventions have emerged as a minimally invasive, promising therapeutic substitute for 
surgery in inoperable or high-risk patients. Moreover, success of transcatheter aortic valve 
replacement (TAVR) over the last decade has motivated the drive for new transcatheter 
therapies targeted specifically to replace and repair the mitral valve. However, the 
engineering and clinical progress is slower than expected due to the challenges that come 
with the mitral valve such as the variety in etiology, the asymmetric and large mitral 
annulus, the dynamic environment of the LV and the critical outflow tract, necessity for 
complex and large delivery systems, and thromboembolism risk factors (12). These 
challenges will be covered more in depth further along in the text. Transcatheter repair and 
replacement are the two approaches that are either offered to patients or under investigation 
right now.  
Percutaneous transcatheter mitral valve repair (TMVRe) methods have been 
classified based on the specific anatomy that they target and are listed as follows:  
1) Leaflets: Edge-to-edge MV repair, leaflet coaptation, leaflet ablation 
2) Annulus: indirect annuloplasty through the coronary sinus or direct annuloplasty  
3) Chordae: percutaneous chordal implantation 
4) LV: percutaneous LV remodeling (1) 
Currently, the MitraClip (Abbott, Chicago, IL, USA) device has the largest clinical 
experience with over 50,000 patients treated worldwide. It provides an edge-to-edge leaflet 
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repair and is the only transcatheter treatment for primary or secondary MR that is guideline 
recommended (12). The procedure is done under the guidance of transesophageal 
echocardiography (TEE) and fluoroscopy, going up the femoral vein and accessing the left 
atrium with an atrial-transseptal puncture. Entering inside the mitral valve (MV), the 
anterior and posterior leaflet free edges are grasped where there is malcoaptation and 
clipped together (13). The EVEREST II study (Endovascular Valve Edge-to Edge Repair) 
was a randomized trial of low-risk patients with primary or secondary MR and 
demonstrated that MitraClip is less effective, but safer than MV surgery, therefore 
receiving Food and Drug Administration (FDA) approval in the US for symptomatic 
patients with significant primary MR and at high surgical risk (14). But further evidence 
was required to approve the benefit of MitraClip in improving secondary MR. The COAPT 
trial was designed as a randomized study to evaluate effectiveness of MitraClip in treating 
clinically significant secondary MR in symptomatic heart failure patients who have been 
deemed as inappropriate for MV surgery. All patients were taking maximally tolerated 
guideline-directed medical therapy (GDMT). The study concluded that in the group that 
underwent transcatheter mitral valve repair as well as GDMT, at a 24 months of follow-
up, lower hospitalization rate for heart failure, lower mortality, and better functional 
capacity and quality of life were observed compared to the group that just took medical 




Figure 2-MitraClip a) delivery system b)clip itself. Reprinted with permission from (16). 
Other percutaneous TMVRe technologies are based on the techniques used in 
chordal  implantation and annuloplasty, and are still under development or in early clinical 
stages (1). These therapies try to mimic the techniques that surgical annuloplasty uses. 
Three catheter-based direct annuloplasty systems are undergoing early clinical studies: the 
Cardioband (Edwards Lifesciences, Irvine, CA), the Mitralign (Mitralign Inc., Tewksbury, 
Massachusetts) and the Accucinch (Guided Delivery Systems, Santa Clara, California) 
(17). Cardioband seems to be the furthest ahead in development, gaining CE-Mark in 2015 
to treat severe FMR. This system is derived from the undersized ring in surgical repair and 
is fully percutaneous and adjustable while also allowing for other interventions on the 
leaflets. An image of the deployed device is shown in Figure 3. The Cardioband Mitral 
System CE-mark trial recently presented 2-year data that showed 79% survival while MR 
≤2+ for  96% of the patients. For technical success-rate, it is crucial to select the proper 
patients for this treatment. A discouraging factor is the long and cumbersome procedure 
which will dissuade cardiologists from its widespread adoption and the review goes on to 




Figure 3- Cardioband device deployed, the implant is a polyester sleeve with radiopaque markers 
spaced 8 mm apart. Reprinted with permission from (19). 
The first experiences of a transcatheter valve replacement for the mitral valve were  
transcatheter valve-in-valve (TViV) and valve-in-ring (ViR) procedures; essentially 
placing a TAVR device inside failed mitral bioprostheses and annuloplasty rings. 
Favorable clinical results with bioprostheses gradually led to them being chosen over 
mechanical valve more often, and with that came a need for re-operative valve 
replacements due to xenograft degeneration which still continues to rise. Repeating cardiac 
surgery to replace failed bioprostheses poses as a clinical challenge as these patients are 
frequently elderly, frail, have ventricular dysfunction, and the procedure carries significant 
morbidity and mortality risk even though surgery is considered the standard of care (20).  
Feasibility of mitral ViV implantation was demonstrated and following studies 
acknowledged satisfactory clinical and hemodynamic outcomes at short- and midterm 
follow-up. The transapical access method also seemed fitting for mitral TViV (21)(22). 
These cases were mostly carried out with the balloon-expandable SAPIEN XT valve 
(Edwards, CA) and in 2014, the Edwards SAPIEN XT valve got CE Mark approval for 
transcatheter mitral ViV procedures (1). Deployment of a 26-mm Edwards SAPIEN XT 
valve (Edwards Lifesciences) into a degenerated 27-mm Carpentier-Edwards prosthesis in 
mitral position is shown in Figure 4. First in-man implantation of a TAVR in a mitral 
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annuloplasty ring was carried out shortly after the first ViV, however, studies show ViR 
poses unique and serious procedural challenges, specifically left ventricular outflow tract 
(LVOT) obstruction and post-procedural MR, and therefore has been linked to having more 
unfavorable outcomes in comparison with ViV (23).  
 
Figure 4-Positioning (A) and deployment (B to D) of a 26-mm Edwards SAPIEN XT valve 
(Edwards Lifesciences) into a degenerated 27-mm Carpentier-Edwards prosthesis in mitral 
position. Reprinted with permission from (21). 
This limited experience shows a glimpse of the promise that transcatheter MV 
replacement (TMVR) can have in becoming the substitute for surgery in high risk MR 
patients, and its capacity to evolve into an easy and fast procedure that is applicable across 
the wide variations of patients and etiologies. However, there are many hurdles that should 
be overcome to design a device that successfully replaces the heart’s most complex valve 
(1). These challenges and requirements are addressed in detail in Table 1.  
Table 1- Complexity and challenges of developing a TMVR device 
Challenges/Requirements for TMVR device development (1) 
Valve Anatomy 
Asymmetrical saddle-shaped mitral annulus (compared to the 
circular aortic annulus) 




Complex subvalvular apparatus consisting of leaflets, annulus, 
chordae tendineae, and papillary muscles. Preservation of this 
structure is essential to maintaining LV geometry 
Irregular geometry of the mitral valve leaflets 
Disease 
Heterogeneity 
MR has multiple causes with different stages of severity and a 
variety of geometrical distortions in the LV anatomy as it 
progresses. Therefore, it is difficult to design a “universal device 






Dynamic changes throughout cardiac cycle in mitral annular 
geometry (shape/size) resulting in an overall reduction of 
annular area up to 30% and a 
reduction of annular circumference of up to 15% 
Maintaining device position within annulus, despite continuous 
cyclic movements and high transvalvular gradients (high 
dislodgment forces) 
Radial stiffness is needed in device to be stable the dynamic 
environment and avoid frame fracture, while keeping 




Deployment in left AV is challenging due to a need for 
transseptal access and the need for a multidimensional, highly 
curved catheter course in order to get inside the left atrium 
The device should not obstruct the LVOT, occlude the 
circumflex coronary artery, compress the coronary sinus, or 
cause major conduction system disruption 
Hemodynamic 
performance 
Paravalvular leak (PVL) minimization is essential but valve 
sealing is a challenge due to the dynamic morphology of the 
mitral annulus, along with the high-pressure gradient generated 
by the ventricle during systole 
 
The landscape of TMVR devices is currently quickly growing with over 30 devices 
under development, Table 2 lists a few of these devices. As seen in Table 2, there are 
significant differences amongst the devices in terms of valve design, position and 
anchoring mechanism. Images of each of these valves and their deployed state visualized 
under fluoroscopy are presented in Figure 6. A major concern for the replacement TMV is 
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making sure that it does not obstruct the LVOT. Reduction of LVOT area has been reported 
after surgical mitral valve procedures with prostheses and annuloplasty rings. Moreover, 
this has been witnessed even after transcatheter mitral interventions done with different 
devices. LVOT obstruction rate secondary to transcatheter mitral ViR is reported as 8.2%, 
rising to 9.3% if the mitral annulus is severely calcified (24). This risk intensifies with 
intra-annular designs that venture into the LV space and requires careful observation and 
comparison with the supra-annular models. Figure 5 displays the different anatomical and 
device design issues that can lead to LVOT obstruction. 
 
Figure 5-Greater device protrusion into the left ventricle, device flaring at its left ventricular 
outflow, larger aorto-mitral angulation, and more pronounced septal bulging can lead to LVOT 
obstruction. Reprinted with permission from (25). 
For the purpose of this discussion, two of the devices that are furthest along in 
clinical evaluation and the design that is modeled in this work are discussed below. 
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TendyneTM Mitral Valve System: The TendyneTM device (TendyneTM Mitral 
Valve System, Abbott Structural, Santa Clara, CA) is an intra-annular, D-shaped, tri-
leaflet, self-expanding porcine pericardium valve placed within a nitinol prosthesis with 
transapical transcatheter delivery and is fully retrievable. The device uses a polyethylene 
tether for anchoring to the LV apex and has an asymmetric, D-shape sealing cuff. In the 
early feasibility trial, 100 patients with grade 3 or 4 MR and mostly secondary (89%) 
received the Tendyne system. Risk of open surgery was prohibitive for all patients. In 96 
patients, the device was deployed successfully, and no mid-procedure were reported. At 30 
days, 6 deaths (6%)  and 2 strokes (2%) happened. The all-cause mortality and cardiac 
mortality were 27.6 % and 15.4% respectively at 1-year. At 1-month in 98.8% of patients 
the MR degree was none or trivial, and at 12-months in 98.4%. The US pivotal trial of this 
device has been initiated based on these results and in early 2020 received CE Mark and 
got approved for use in Europe (25)(13)(26). Figure 6, U and W show this device. 
IntrepidTM TMVR System: The Medtronic IntrepidTM valve system (IntrepidTM 
TMVR System, Medtronic, Inc., Redwood City, CA) is an intra-annular, circular, tri-
leaflet, self-expanding bovine pericardium valve placed on a nitinol stent with transapical 
transcatheter delivery. Radial forces and a barbed metal frame are used for anchoring the 
device within the mitral annulus. In the early experience with this device, 50 patients with 
symptomatic, severe MR received the device with successful implantation in 96% of 
patients. Figure 6, M and N show this device. The 30-day mortality was 14% with no 
disabling strokes or repeat interventions and at a follow-up of 173 days, only mild or no 
residual MR was reported. The US pivotal trial APOLLO has been formed following these 
results. This trial is an ongoing study that has two parts, the first  part randomizes severe, 
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symptomatic MR patients who have acceptable surgical risk  to TMVR vs. conventional 




Figure 6- Transcatheter mitral valve replacement (TMVR) devices. A, AltaValve. B, Fluoroscopic 
image of the AltaValve. C, Caisson TMVR. D, Fluoroscopy image of the Caisson TMVR. E, 
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CardiAQ Valve. F, Fluoroscopy image of the CardiAQ Valve. G, CardioValve. H, Fluoroscopy 
image of the CardioValve. I, Fortis. J, Fluoroscopy image of the Fortis. K, HighLife. L, 
Fluoroscopy image of the HighLife. M, Intrepid TMVR. N, Fluoroscopy image of the Intrepid 
TMVR. O, MValve System. P, Fluoroscopy image of the MValve System, Q, Neovasc Tiara. R, 
Fluoroscopy image of the Tiara. S, Sapien M3 System. T, Fluoroscopy image of the Sapien M3 
System. U, Tendyne. W, Fluoroscopy image of the Tendyne. Reprinted with permission from (27). 
 
Table 2-Overview of TMVR designs under clinical testing and development 
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Sapien M3TM: The Sapien M3TM valve system (Sapien M3, Edwards Lifesciences, 
Irvine, CA) is an intra-annular, circular, bovine pericardium valve that is balloon-
expandable, placed on a cobalt-chromium frame that is fixed in position with a nitinol 
coiling system wrapped around the native mitral valve leaflets and uses a transseptal 
transcatheter delivery. This design is based on the successful Sapien 3 TAVR prosthesis, 
with an added polyethylene terephthalate skirt to ensure a seal is formed between the nitinol 
docking system and the native valve. 10 patients with severe primary, secondary or mixed 
MR were considered for the initial in-human study. 9 cases had successful implants, and 
trivial or no MR was reported in all cases. 30-day outcomes showed no unfavorable cases 
of rehospitalization, stroke, left ventricular outflow tract obstruction, myocardial 
infarction, embolization, device migration or conversion to open surgery although a 
paravalvular leak was developed in one case, which was then treated with a closure device. 
This was a demonstration of Sapien M3 valve feasibility and safety for high surgical risk 
patients with severe MR (25). Figure 6, S and T show this device. 
Although by now the necessity and feasibility of a TMVR has been proven, it is 
essential to understand the modes of failure and the durability of the device in order to 
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consider it as a standard of care. The intention of any medical treatment is to provide the 
patient with the optimal long-term cure or relief. Therefore, heart valve prosthesis long-
term durability should preferably be longer than the expected lifespan of the patient it is 
being used for (28). The International Organization for Standardization currently requires 
valve prostheses to meet certain durability targets before certifying them for 
commercialization. Each valve must undergo a certain amount of sterilization cycles, at 
least 200 million cycles (equaling  5 years of durability)(29). Undoubtedly, with the limited 
clinical experience of TMVR devices, the actual durability and failure modes are still not 
identified and there is great need for research and knowledge in this area. Even for TAVR 
devices, this information is not adequate as this treatment has only become prevalent since 
obtaining FDA approval in 2011 and not even a ten year durability analysis is possible 
(29). 
Some insight can be drawn from surgical aortic valve replacements and studies that 
have been done with TAVR for a 5-year outcome. In general, bioprosthetic surgical aortic 
valves have had a more favorable hemodynamic performance in comparison with 
mechanical aortic valves and have the advantage of not needing life-long anticoagulation 
therapy, but fall short in terms of durability as a result of calcification and/or fatigue-related 
structural degeneration (30). Both surgical and transcatheter bioprostheses are made from 
biological tissues such as bovine or porcine pericardium and are at a risk of structural valve 
degeneration (SVD), a multifactorial process that results in the calcification and 
degeneration of the leaflets which ultimately lead to valve stenosis, leaflet tear and 
regurgitation (29). The most common failure mechanisms that have been witnessed among 
the reported cases of transcatheter heart valve (THV) SVD are tissue ingrowth (pannus), 
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incomplete THV expansion and leaflet calcification (31). Increased leaflet mechanical 
stress has been identified as one of the main mechanisms in the pathogenesis of SVD that 
cause the valve leaflet tissues to be thickened (29). Moreover, in a finite element analysis 
of leaflet fatigue due to cyclic loading that compared a transcatheter aortic valve (TAV) 
and a surgical aortic valve (SAV) with same loading conditions. In comparison with the 
SAV leaflets, higher stresses, strains, and fatigue damage was witnessed in the TAV 
leaflets (30). Therefore, it is essential to identify and understand any condition that can 
induce higher mechanical stress on transcatheter valve leaflets as it may accelerate SVD. 
The first aim of this work is to quantify the stress distribution on a potential TMVR design 
and compare to a surgical mitral valve replacement device under the same loading 
conditions.  
Valve thrombosis is another common mechanism of failure that occurs in 
bioprosthetic valves (32). In patients undergoing surgical aortic valve replacement 
(SAVR), thrombosis can happen in the early postprocedural phase in up to 15% of cases. 
Several theoretical mechanisms have been proposed to explain why risk of thrombosis in 
THVs could potentially be higher than SAVR: 1) comorbid prothrombotic conditions such 
as cancer, 2) the metal THV frame is a potential cause of thrombosis, 3) under-expansion 
of the valve can cause folds in the leaflet resulting in potential spots for thrombosis, 4) 
native leaflets may create regions of reduced blood flow and stagnation (31). Although 
thrombosis is usually treated successfully with anticoagulant therapy, it can also lead to 
inflammation and consequent calcification of the leaflets (29) and studies have expressed 
that currently, the optimal management of THV thrombosis is still not clear (31). 
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Therefore, it is crucial to study and understand the risk of thrombosis and its causes in 
THVs.  
Currently, blood residence time (BRT) and wall shear stress are recognized as 
factors related to thrombus formation, providing a method of quantifying risk of thrombosis 
in computational simulations. High wall shear stress (WSS) results in platelet activation, 
hemolysis, and endothelial cell damage and is related to thrombotic risk. Conversely, 
regions of flow recirculation are linked to lower WSS and high residence time (RT), and 
combined with prior high shear stress exposures, might potentially add to thrombus 
formation risk. WSS, a measure of red blood cell exposure to different shear conditions, 
has previously been reported as an important factor for comparing various anatomies and 
clinical scenarios. In this context, RT is a way of quantifying fluid stagnation in a specific 
location, helping to give a time frame in the process of thrombus formation (33). The next 
aim of this work is to quantify BRT and understand the risk of thrombosis in TMVR 
devices. As explained previously, TMVR designs can be in either supra-annular or intra-
annular position, and this study aims to compare the risk of thrombosis between these two 
designs and ultimately compare the risk of thrombosis to that of a surgical mitral valve 
replacement device. For that purpose, a computational model of the left atrium and 
ventricle will be built that incorporates the movement of the left ventricle and the valve 




CHAPTER TWO: MATERIALS AND METHODS 
 
TMV performance is assessed through understanding leaflet stress distribution and 
making precise flow measurements close to the TMV leaflets, which pose challenges in 
the clinical settings as the imaging modalities that are currently available are limited in 
temporal and spatial resolution. Therefore, to investigate the stress distribution and flow 
field around the TMV device in intra and supra-annular positions, a combination of 
computational modelling and experimental testing were utilized. The method is explained 
step by step. 
2.1. Geometry  
The first step to building the computational models was designing the valve and 
LV geometry. For the surgical mitral valve replacement, a 25-mm Carpentier-Edwards 
(CE) PERIMOUNT Magna mitral valve (Edwards Lifesciences, CA) device was used. This 
surgical bioprosthetic valve has a 24 mm Elgiloy frame that the bovine pericardium leaflets 
are mounted on. As no TMV is commercially available, for the TMV models, the 26-mm 
Edwards SAPIEN 3 (Edwards Lifesciences, Irvine, CA) device was used to construct the 
SAPIEN M3 (Edwards Lifesciences, Irvine, CA) TMV design. The SAPIEN M3 valve has 
a balloon-expandable cobalt-chromium stent exactly like the SAPIEN 3 with bovine 
pericardial leaflets mounted on the stent.
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The SAPIEN M3 also has a polyethylene terephthalate skirt around it ensuring a seal is 
made between the docking system and the valve, therefore that was also built around the 
valve. Both valves can be seen in Figure 7. A Mitutoyo Digital caliper (Mitutoyo Corp, 
Kanogawa, Japan) was used to measure the leaflet thickness; average thicknesses of 0.50, 
and 0.32 mm were reported for CE PERIMOUNT Magna bioprosthesis, and SAPIEN 3, 
respectively. 
 
Figure 7- Geometry of a) Edwards SAPIEN 3 and b) CE PERIMOUNT Magna valves built with 
Solidworks. The grey area identifies the stent around the leaflets shown in beige 
Patient-specific anatomical CT data of the left side of the heart were obtained over 
one full cycle from a patient in heart failure with an ejection fraction of 0.35. Image 
segmentation was done with Mimics Materialise software to build a 3D model as seen in 
Figure 8a. Initial surface smoothing was done with Mimics to generate the initial mesh file 
output as seen in Figure 8b. The mesh was then exported to Geomagic Design to fit a 
surface to the smoothed mesh, Figure 8c. Finally, after obtaining a full smoothed surface 
of the model, the aortic root and aorta were cut from the model as they were irrelevant to 
the TMV simulation and to simplify the analysis, Figure 8d. The four pulmonary veins 
entering the left atrium are the inlets of the model and the aortic root is the outlet. The 
valves were then placed inside the left heart model. Three models were built with 
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Solidworks: 1) THV in intra-annular position, 2) THV in supra-annular position and 3) a 
surgical mitral valve in intra-annular position. All three models are seen in Figure 9. 
 
Figure 8- Stages of building left heart computational model: a) rough model obtained after 
segmentation, b) smoothed mesh output from Mimics, c) surface fitted to the mesh with Geomagic 
Design and d) final left heart model after removing aorta at the aortic root 
 
Figure 9- Final computational models with transcatheter valve (Edwards SAPIEN 3) placed in a) 
intra-annular position, b) supra-annular position and surgical valve (CE Perimount Magna) 
placed in intra-annular position 
2.2. Experimental Setup 
2.2.1. In Vitro Pulse Duplicator System 
For the computational simulations, the pressure gradient on the mitral valve device was 
necessary for each of the two valves with physiological loading conditions. Each 
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bioprosthetic heart valve was placed in the pulse duplicator system (BDC Labs, Wheat 
Ridge, CO) in mitral position. The Carpentier-Edwards PERIMOUNT Magna mitral 
bioprosthesis is positioned on a silicone washer and the sewing ring is sutured to it to hold 
the valve in position. In addition, the SAPIEN 3 TAV was put inside a silicone washer, 
making sure that the TAV frame (stent) bottom was level with the silicone washer bottom. 
In the aortic valve position, a bileaflet mechanical heart valve is put in the silicone ventricle 
to maintain aortic outflow. A picture of the setup is provided below in Figure 10. The input 
parameters for the pulse duplicator were in accordance with the international standard ISO 
5840: 2015 recommendations for testing prosthetic heart valves; that is, heart rate of 70 
beats/min, mean aortic pressure of 100 mm Hg, and cardiac output of 5 L/min. The 
peripheral resistance in the setup and the compliance are controlled to ensure physiological 
flow conditions. When the pump's piston moves during every stroke, the pressure around 
the compliant silicone ventricle changes, ejecting the flow through the aortic valve. As a 
blood analog fluid, a recirculating fluid of 45% by volume glycerin solution (99% The 
Science Company, Denver, CO, USA) in phosphate buffered normal saline solution 
(Research Products International, Mount Prospect, IL, USA) was used. The running 
solution has a viscosity of 3.45 cP, a density of 1.12 g/cm3, and a refractive index of 1.39 
at 37°C. To measure the pressure in the atrium and left ventricle, strain gauge pressure 
transducers (Utah Medical Products, Midvale, UT, USA) were positioned inside the pulse 
duplicator at 35 mm downstream and 105 mm upstream of the bioprostheses in mitral 
position. Prior to the tests, the pressure transducers were calibrated with Delta-Cal Pressure 
transducer simulator/tester (Utah Medical Products, Inc). In addition, an electromagnetic 
flowmeter (Model 501,Carolina Medical Electronics Inc, East Bend, NC, USA) was used 
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to measure flow rate in the system. Specific details on the in-vitro testing were obtained 
from (34).  
 
Figure 10-Pulse duplicator experimental setup, the silicon heart chamber can be seen. 
During the experiment, leaflet motion is captured with a high-speed camera (Sony 
DSC-RX10M3) positioned underneath the mitral valve position at a rate of 960 frames per 
second. The images were digitized in Solidworks; for each leaflet edge, the center point 
was tracked during the full cardiac cycle, calculating the distance of the tip from the center 
of the valve. The values from all three leaflets were averaged and used as the displacement 
curve of the leaflet. Sample images obtained during the experiment can be seen in Figure 
11. 
Figure 11-Photos obtained of the valve motion during the experiment 
 
2.3. Computational Simulations 
2.3.1. Finite Element Modeling: Leaflets 
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The leaflet geometry for the bioprosthetic valves was found through 3D scanning 
of the geometry, a NextEngine 3D Laser Scanner (resolution of 100 micrometers, 
NextEngine, Inc., Santa Monica, CA) was used. RapidWorks and SOLIDWORKS 
packages were used for the surface reconstruction of valves. One leaflet geometry was 
reconstructed, and mirrored using symmetry for the other two leaflets. The leaflets’ IGES 
formats were obtained for FE simulation. Subsequently, the leaflets underwent mesh 
generation with HyperMesh (Altair Engineering, Inc., Troy, MI), in which a mapped mesh 
was used to discretize the geometry. After that, the mesh was taken into ABAQUS/Explicit 
solver. The geometry of CE PERIMOUNT Magna and SAPIEN 3 leaflets were meshed 
using 6924 and 6714 ABAQUS S4 shell elements, respectively. The element size in the 
simulations was determined based on displaying mesh density independence, with less than 
1% difference.  The mesh for each of the leaflets is presented in Figure 12.
 
Figure 12-Mesh of valve leaflets, a) SAPIEN 3 and b) Perimount Magna 
  It was assumed that throughout the leaflet, leaflet thickness is uniform and constant, 
equivalent to  0.50, and 0.32 mm for CE PERIMOUNT Magna bioprosthesis, and SAPIEN 
3, respectively. A MATLAB code was written to find the material orientation of the shell 
elements. The leaflet density was 1100 kg/m3. On the atrial side of the leaflets, the pressure 
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gradient waveforms obtained across the valve from the experimental tests were applied. In 
addition, to resemble viscous damping effects of surrounding fluid, a Rayleigh damping 
coefficient α was added. In the ABAQUS/Explicit package, a form of strain energy 
potential provided to characterize anisotropic materials is the generalized three-
dimensional Fung strain-energy function. The bioprosthetic leaflets were assumed to be 
pseudo-hyperelastic anisotropic materials in the FE simulations.  
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where Ψ is the strain energy per unit of reference volume. 𝐷 and 𝑐 describe the 
temperature-dependent material parameters, 𝐽𝑒𝑙 stands for the elastic volume ratio and 𝑄 is 
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2.3.2. Optimization Framework: Leaflets 
A global optimization approach was implemented to obtain the 3D mechanical 
properties of the leaflets.  Initial estimate values for optimizing Fung’s  model were taken 
from Abbasi et al (34). Executed in Isight (Simulia, Providence, RI), a particle swarm 
optimization (PSO) method (34) is used to identify the optimized leaflet material 
parameters as well as the viscous damping coefficient. The hemodynamic data from 
experiments with the pulse duplicator setup was used for the optimization. The 
displacement of the midpoint on the leaflet edge from the experiments in the pulse 
duplicator system was used as a target to match the displacement of the same point in the 
FE simulation. The objective function is defined as the sum average of the squared 
differences between the displacement values of the simulation results and experimental 
results. To increase computational efficiency, only one leaflet motion during one cardiac 
cycle was simulated. The optimization process ended once the objective function value 
dropped below 5×10-5. For optimizing the material properties of each valve leaflet, the 
pressure obtained from experiments with the respective valve was used.  
2.3.3. Finite Element Simulation: Leaflets 
After finding the optimized material property parameters, the leaflet simulation was 
run under physiological loading conditions. For a fair comparison of  stress values between 
the two valves’ leaflets, physiological loading conditions consisting of simultaneously 
acquired LA and LV pressures throughout one cardiac cycle was obtained from (35), 
enabling the calculation of the pressure gradient across the mitral valve. It should be noted 
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that these pressures were obtained from patients undergoing first-time coronary bypass 
surgery and had either trivial or mild mitral regurgitation. The mean ejection fraction 
among the patients was 0.38±0.19. A Savitzky-Golay smoothing filter with an order of five 
was applied to the data to get rid of unwanted noise.  
2.3.4. Finite Element Modeling: Left Ventricle (LV) 
In order to simulate the LV motion during the cardiac cycle, a finite element model 
of the LV was built. The geometry was meshed with S3 elements with a mesh size of 1 
mm and a total of  62381 elements. The majority of patients undergoing TMVR in clinical 
trials have a left ventricular ejection fraction (LVEF) of between 30-40% (24). The patient 
in question had an approximate ejection fraction of 35%. Geometric models were built for 
each time frame that the CT scans provided and were used as a guide for LV contraction 
and expansion simulation. The end-diastolic state, when the heart is at its largest and is full 
of blood ready to be pumped, was considered as reference, and displacement in respect to 
this reference point was considered. An image of the LV at end diastolic and end systolic 
position are provided in Figure 13.  
 
Figure 13-LV in fully expanded and contracted configuration with an ejection fraction of 0.35. The 
apex at end systolic volume (apex) and end diastolic volume (apex_EDV) can be seen 
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The material was assumed to be hyperelastic and a reduced polynomial strain 
energy function was used. The form of the reduced polynomial strain energy potential 
(N=4) is: 












where Ψ is the strain energy per unit of reference volume. 𝐷𝑖 and 𝐶𝑖0 stand for the 
temperature-dependent material parameters, 𝐽𝑒𝑙 describes the elastic volume ratio, and 𝐼1̅ 
is the first deviatoric strain invariant. To simulate viscous damping effects of the 
surrounding fluid, a Rayleigh damping coefficient α is added to the model. Compressibility 
can be defined by specifying nonzero values for 𝐷𝑖 . Initial guesses for the model were 
derived from the experimental stress/strain data found in (36) through fitting the 
hyperelastic material model in ABAQUS. 
2.3.5. Optimization Framework: LV 
In order to simulate LV contraction, the position of the apex was tracked during the 
cardiac cycle and use as the target for optimization. A global optimization framework was 
used to match the apex displacement of the computational model to the observation from 
the CT derived models. The apex at the two states can be seen in Figure 13. The LV 
material parameters were optimized with a particle swarm optimization (PSO) algorithm 
(34) executed in Isight (Simulia, Providence, RI). The apex displacement in x, y, z in the 
FE simulation was optimized with the results of the apex displacement in x, y, z during the 
cardiac cycle. The objective function in the optimization procedure minimizes the average 
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of the sum of the squared differences for the displacement from CT data and simulation 
results. Once the objective function drops below 5×10-5, the optimization process ends.  
2.3.6. Finite Element Simulation: LV 
After finding the optimized material property parameters, the leaflet simulation was 
run under physiological loading conditions for the LV obtained from (35). It should be 
noted that the purpose of this simulation is solely to simulate the LV movement and values 
of stress are irrelevant, only displacement values are of interest. 
2.3.7. Computational Fluid Dynamics (CFD) Modeling 
The aim of CFD modeling is to use one-way Fluid-Structure Interaction (FSI) 
simulations to simulate the three-dimensional flow field of the TMVs in ANSYS Fluent 
(ANSYS, Canonsburg, PA, USA). The fluid domains were discretized into unstructured 
tetrahedral elements using Pointwise (Pointwise Inc., Fort Worth, TX, USA). The number 
of elements in the simulations were determined based on displaying mesh density 
independence, with a difference of less than 1%. Blood was considered a Newtonian fluid 
with density and the viscosity of 1,060.0 kg/m3 and 0.0035 kg.s/m2, respectively. Initially, 
steady-state simulations of the surgical, intra-annular and supra-annular models were run 
to get a  preliminary visualization of the flow field. A constant inlet pressure of 1600 kPa, 
equivalent to the inlet pressure of the left atrium was used. The pressure at outlet was 
assumed to be zero. A k-epsilon turbulence model was used to simulate the turbulent flow. 
The residuals were monitored to reach 1×10-6. However, the movement of the leaflets and 
LV need to be incorporated into the CFD model in order to fully simulate the left heart 
during the cardiac cycle. Codes were written to create frames of the leaflet movement from 
the FE simulation of the leaflets. For each leaflet, a fine cloud mesh is generated at every 
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0.2 ms based on the FE simulation. The same was done for the LV. Consequently, a user-
defined function (UDF) uses the cloud meshes to update the leaflets’ surface grids at each 
time-step. ANSYS Fluent has a dynamic mesh feature that includes a cell size/skewness-
based remeshing scheme and a diffusion-based smoothing, both of which are used at each 
time-step to update the mesh of 3D tetrahedrons in the computational grid. Tecplot 360 
(Tecplot USA, Bellevue, WA, USA) was used to visualize the results
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CHAPTER THREE: RESULTS 
 
3.1. Experimental Results 
After testing the two bioprosthetic heart valves with the pulse duplicator, the results 
of the flow and pressure waveforms are shown in Figure 14. The effective orifice area of 
the bioprostheses was calculated based on the Gorlin equation. The bioprosthesis effective 
orifice area is 2.03 ± 0.029cm2 for Edwards SAPIEN 3  and 1.75 ± 0.024 cm2 for CE 
Perimount Magna.  
 
Figure 14-Raw pressure and flow waveforms obtained from experimental testing of each valve 
with the pulse duplicator test setup
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The pressure waves were used to find 3D mechanical properties in the optimization 
procedure for the two valve leaflets. Initial estimates were taken from a study (34) for the 
valves in aortic position. Using PSO method in Isight, the displacement of the midpoint on 
the leaflet edge in the FE simulation was matched to the averaged experimental data 
through optimizing the Fung model parameters of the leaflets and the Rayleigh damping 
coefficient. In the optimization procedure, just one leaflet motion was fitted to the averaged 
displacement curve.  The sum of the squared difference of the simulated and measured 
displacement for the midpoint of the leaflets was minimized through changing material 
parameters. The optimized 3D anisotropic Fung model material parameters are shown 
below in matrix format. Furthermore, the estimated values for the material parameter, c 
and viscous damping, 𝛼 in the Fung model are presented in Table 3. Optimization results 
are seen in Figure 15. It took around 500 iterations for the optimization results to become 
in agreement with the experimental data. In addition, in Figure 15, the results of using the 
initial material properties from (34) are plotted with the results obtained from the optimized 
material parameters. 
 
Figure 15- Optimization results for the averaged leaflet tip displacement for each valve. Each 




Table 3-Material parameter and viscous damping coefficient for 3D anisotropic Fung model 
Bioprosthesis c (material parameter, Pa) 𝛼 (viscous damping, 1/s) 
CE PERIMOUNT Magna 28338 14695 








62.25    33.50 53.90 16.50   51.50 41.40
 63.60  44.40  65.43  61.66  18.34
 62.71  40.50  63.00  54.71
 13.90  15.71  29.50















80.52    37.37 61.00 20.31   40.00 38.91
 78.30 45.03  74.76 73.96  25.82
86.30  40.32  64.70  53.04









3.2. Finite Element Analysis Results 
3.2.1. Leaflet Stress Distribution  
The maximum in-plane principal stress distribution for 25-mm CE PERIMOUNT 
Magna and 26-mm SAPIEN 3 utilizing the optimized parameters were obtained with the 
same physiological loading on both valves for a fair assessment of stress values. Stress 
distribution is shown separately for SAPIEN 3 during systole and diastole in Figure 16 ,a, 
b and Figure 17 a, b, respectively and for CE PERIMOUNT Magna in Figure 16 c, d and 
Figure 17 c, d. To make sure stress values are independent of the cycle, two cardiac cycles 
were simulated. During systole, the boundary edges for the two valve leaflets had higher 
stress areas compared to the rest of the leaflet. The maximum stress value on the leaflet 
during systole reached to 4.75 and 16 MPa for the CE PERIMOUNT Magna, and SAPIEN 
3, respectively. In diastole, the maximum stress recorded for the PERIMOUNT Magna and 
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SAPIEN 3 leaflets was 0.19 and 0.23 MPa, respectively. For both valves, regions of high 
stress were located around the commissures at the tip of the leaflets and in the mid-bottom 
section of the leaflets in the full open state. The maximum in-plane strain distribution of 
26-mm SAPIEN 3 and 25-mm CE PERIMOUNT Magna are also shown in Figure 18 
during systole and Figure 19 for diastole. At systole, the maximum leaflet strain value for 
the CE PERIMOUNT Magna, and SAPIEN 3 was 0.33 and 0.25, respectively. During 
diastole, the maximum strain value was 0.13 and 0.11, for PERIMOUNT Magna and 
SAPIEN 3 leaflets, respectively. With the PERIMOUNT Magna valve, high strains are 
seen in the mid-belly region of the leaflet, but maximum values during systole, like with 
stress, are seen closer to the commissures. 
 
Figure 16- Maximum in-plane principal stress at peak systole, a) side view, b) bottom view 




Figure 17-Maximum in-plane principal stress at peak diastole, a) side view, b) bottom view 
SAPIEN 3, c) side view, d) bottom view PERIMOUNT Magna 
 
Figure 18-Maximum in-plane principal strain at peak systole, a) side view, b) bottom view Sapien 
3, c) side view, d) bottom view Perimount Magna
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Figure 19-Maximum in-plane principal strain at peak diastole, a) side view, b) bottom view 
Sapien 3, c) side view, d) bottom view Perimount Magna 
The von Mises stress was also plotted in systole and diastole, shown respectively 
in Figures 20 and 21. The peak leaflet stress value during systole for the CE PERIMOUNT 
Magna, and SAPIEN 3 reached to 5 and 9.2 MPa, respectively. During diastole, the peak 
stress value of the PERIMOUNT Magna and SAPIEN 3 leaflets reached to 0.9 and 4.5 
MPa, respectively. During systole, in agreement with the maximum in plane stresses, the 
von Mises stress also shows high stress regions were primarily observed in the fixed 




Figure 20- Von Mises stress at peak systole, a) side view, b) bottom view SAPIEN 3, c) side view, 
d) bottom view PERIMOUNT Magna 
 
Figure 21- Von Mises stress at peak diastole, a) side view, b) bottom view SAPIEN 3, c) side 
view, d) bottom view PERIMOUNT Magna 
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In order to better demonstrate how stress values differ between the two valves under 
the same loading condition, the maximum in-plane principal stress histograms are 
presented in Figures 22 and 23 for systole and diastole, respectively. During systole, 
SAPIEN 3, 38.5% of elements had stress values of more than 400 kPa compared to 20.2% 
for the PERIMOUNT Magna. During diastole, 86.7% of the elements in PERIMOUNT 
Magna had a stress of up to 100 kPa in comparison to 62.8% of SAPIEN 3 elements in this 
range. Over 35% of SAPIEN 3 elements had stress values of over 100 kPa. 
 





Figure 23- Distribution of maximum in-plane principal stress at peak diastole at each node for 
each valve 
3.2.2. LV Motion Simulation 
An optimization procedure was used to simulate the LV motion through identifying 
the hyperelastic material properties. Geometric models of the LV during the cardiac cycle 
were built from CT data and the apex displacement was found and tracked. The end-
diastolic state was used as the reference point and the displacement relative to that was 
found. The initial guesses were derived from experimental stress/strain data and fitting a 
reduced polynomial hyperelastic material function. Reduced polynomial model parameters 
for the left ventricle were found with the PSO method in Isight through targeting the 
displacement of the apex for each coordinate x, y, z. Figure 24 a,b,c, shows the result of 
the optimization for coordinates x, y and z, respectively. For computational efficiency in 
the optimization procedure, only the apex was monitored. In addition, in Figure 24, the 
initial material properties’ results are plotted with the optimized material parameters’ 
results from the simulations. Looking at timing and magnitude, a clear difference is seen 
between them. The maximum displacement between the two simulations was 80, 85 and 
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42% different for x, y and z, respectively. In Figure 24 d, the displacement magnitude 
resulting from the optimized model and the target can be seen. The maximum target and 
optimized displacement is 10.24 and 10.46 mm, respectively. The optimized material 
parameters are listed in Table 4.      
Table 4-Material parameters for reduced polynomial model for the left ventricle 
 𝑪𝟏𝟎 𝑪𝟐𝟎 𝑪𝟑𝟎 𝑪𝟒𝟎 𝑫𝟏 𝑫𝟐 𝑫𝟑 𝑫𝟒 
Left 
Ventricle 
3210689 6055235 -2581107 1348871 3.5e-5 3.5e-5 5.2e-5 5.7e-5 
 
Figure 24- Optimization results for the apex displacement in each coordinate x, y and z. Each 
graph compares the optimized FE simulations with the target data and simulation with initial 
parameters 
3.3. Computational Fluid Dynamics (CFD) Results 
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The aim of CFD modeling in this work is to initially prove the feasibility of reliable 
CFD modeling within the LV anatomy with steady-state simulations and in the next step, 
use one-way Fluid-Structure Interaction (FSI) to fully simulate the three-dimensional flow 
field. The FE simulations of the valve leaflets and LV are used for FSI modeling. Codes 
were written to create frames of the leaflet and LV movement from the FE simulations. 
Essentially, at every 0.2 ms, for each leaflet, a fine cloud mesh is generated based on the 
FE simulation, and the same for the LV which would then be read using a user-defined 
function (UDF). This function updates the leaflets’ and LV’s surface grids at each time-
step with the cloud meshes. CFD models were built for the surgical, supra-annular and 
intra-annular transcatheter valves and the results of the steady-state simulation are 
presented in Figure 23. A constant inlet pressure of 1600 kPa is assumed in the simulation.  
In Figure 25 a, b, c, a slice has been made in the pressure field at the tip of the leaflets 
exactly at the position that flow exits the valve. The valves are in the zero-pressure gradient 
form at the beginning of diastole when they start to open. The central jet in the intra-annular 
model has lower pressure compared to the surgical and supra-annular model while the 
surgical valve has the largest high-pressure region. Images d, e, f in Figure 25 display the 
same slice in the velocity field and the intra-annular jet has the highest velocity at the 
center. In the steady-state conditions, flow velocity and pressure are inversely related, so 
the results for the valves are reasonable. A clear difference between the flow velocity and 
pressure at the valves is seen between the intra and supra-annular position, confirming the 
need to study and investigate the effects of valve position on the flow and the 
hemodynamics. Parts g, h and i in Figure 25 show the velocity vector field within the LA 
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and LV. The flow jet is clearly visible within the anatomy, showing that the solution has 
fully converged. As the walls of the LV are stationary in the steady-state model, the flow 
around the walls has very low velocity (less than 0.2 m/s) but when the movement of the 
LV is incorporated in the model, the dynamic anatomy will directly affect the flow field. 




CHAPTER 4: DISCUSSION 
 
In this study, the first aim was to predict and compare the durability of TMVR 
devices to surgical bioprosthetic mitral valve replacements and used a finite element 
modeling approach to assess stress distribution and justify its relation to durability. The 
leaflets’ three-dimensional anisotropic mechanical properties were defined for a 
commercially available and well-examined surgical bioprosthesis (i.e., Carpentier Edwards 
PERIMOUNT Magna mitral heart valve) and a TMVR device under clinical investigation 
(Edwards SAPIEN M3).  With a pulse duplicator system, the valves were tested under 
dynamic physiological loading conditions. With an optimization method, the 3D 
anisotropic mechanical properties of the leaflets were adjusted to become compatible with 
the results of the experiment. Finite element analysis with the optimized results, yielded 
the maximum in-plane principal stress and strain distribution for the two valves. These 
were compared at both systole and diastole to help predict durability. 
It is essential to highlight that clinical data is the first and foremost predictor of 
durability, however, in the case of TMVR devices, when there is not even yet an approved 
device, such data do not exist. Even in the case of TAVRs, long-term data are still scarce. 
However, long-term durability is a critical element in choosing a suitable replacement heart 
valve for the mitral valve. Therefore, the only choice left is to compare with bioprosthetic 
valves that have relevant long-term clinical data available; in this case, surgical   
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bioprosthetic mitral valve replacements and to compare surgical aortic valve replacement 
(SAVR) and transcatheter aortic valve replacement (TAVR) and draw cautious conclusion 
from that. In these circumstances, the importance of computational modeling and 
simulation in providing insights on TMVR durability in combination with clinical data is 
emphasized.  
Leaflets degeneration in surgical bioprosthetic valves happens through two 
separate, but potentially cooperating mechanisms: calcification and fatigue-induced 
structural deterioration. Since the TMV leaflets, similar to commercial TAV leaflets, are 
made from bovine or porcine pericardium tissue that has been chemically treated, it can be 
predicted that the same failure mechanisms apply to the structural deterioration of TMVs 
as well. Structural valve degeneration (SVD) happens gradually, eventually causing valve 
dysfunction secondary to stenosis, regurgitation, or a combination of stenosis and 
regurgitation (29). Although structural valve degeneration definition is varied in the 
literature, at 10 years, the overall SVD rate for surgical bioprostheses is less than 15% (34).  
In 2014, Bourguignon et al. studied the Carpentier-Edwards PERIMOUNT 
pericardial bioprosthesis in the mitral position in terms of the long-term durability and 
reported the longest-term follow-up data with this prosthesis, with some patients at 20 years 
post-op. 404 consecutive patients (mean age, 68 years; 53% female) were studied. The 
results for SVD in this study showed the overall actuarial freedom from SVD is 83.9% ± 
2.7% and 23.7% ± 6.9% at 10 and 20 years, respectively. The expected valve durability 
was acceptable for the long-term, with a median survival time (MST) of 16.6 years before 
valve deterioration. The freedom from reoperation for SVD was 86.3% ± 2.5% and 40.5% 
± 8.0% at 10 and 20 years, respectively, with an MST of 19.0 years. The expected valve 
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durability was compared with the sample life expectancy after MVR in different age 
groups, concluding that at least for 90% of the cohort, the expected valve durability was 
greater. The study concluded the Carpentier-Edwards PERIMOUNT pericardial 
bioprosthesis is a dependable option for a tissue valve in the mitral position, particularly in 
patients>60 years old (37). 
SAVR and TAVR can be compared even though clinical data beyond 5 years about 
long-term durability of TAVRs is currently limited. Bourguignon et al. (38) reported that 
recipients of CE PERIMOUNT surgical aortic valve aged 60 or younger had freedom from 
reoperation rates (attributable to structural valve deterioration) of 88.3 ± 2.4 and 38.1 ± 
5.6% at 10 and 20 years, respectively. Dvir conducted a study on patients (n=378) with up 
to 10 year follow up post TAVR. These patients’ valves were one of the following: 
Edwards Sapien XT, Cribier Edwards and Edwards Sapien. In sum, 35 SVD cases were 
reported: around two-thirds showed intra-prosthetic aortic regurgitation and the rest mixed 
disease or valvular stenosis. This study concluded an estimated SVD rate of approximately 
50% at 8 years, however, due to the SVD definition in this study, the actual SVD incidence 
could have been overestimated (29). 
The key factors related to SVD after SAVR can be split into 3 categories: those 
associated to the patient directly, cardiovascular risk/comorbid conditions, and valve 
associated factors. In the first group, in most studies, bioprosthesis durability is related to 
age at the time of valve implantation. At a 10-year follow-up, the SVD rate in elderly 
patients is commonly less than 10%, however in patients below 40, it can rise to 20% to 
30%. Accelerated SVD is also related to larger body surface area, possibly due to larger 
hemodynamic stress and less tolerance for the adverse results of stenosis or regurgitation. 
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Amongst the valve related factors, the most important is the prosthesis size being too small 
and prosthesis-patient mismatch (PPM) which result in unusually high gradient across the 
valve because of the higher mechanical stress, potentially contributing to increased SVD 
incidences (29). 
As there are few patients with long-term follow-up data, it is hard to evaluate the 
factors related to SVD after TAVR, leading to few cases of SVD events. However,  
considering that transcatheter valves are basically bioprosthetic valves, the risk factors of 
surgical bioprostheses can be expected to be related to post TAVR bioprosthetic 
deterioration, with the addition of specific considerations to the TAVR field (29).  The 
differences between TAVR and SAVR consist of: how the native valve is dealt with at 
implantation (in TAVR the native cusp calcifications are left whereas in SAVR, the 
calcifications are removed completely), paravalvular leakage risk (due to the different 
TAVR implantation method in comparison to suturing techniques in surgical valve) and 
the need to develop low profile delivery systems for TAVR as well as crimping the valve 
leaflets, all of which could contribute to decreasing valve durability (29)(28). These are all 
issues that a TMVR device faces as well, therefore posing as potential threats against 
TMVR durability. 
Event though TAVR prostheses are made from leaflet material that is similar to 
surgical bioprostheses, higher mechanical stress levels are observed on TAVR valves due 
to how leaflet tissue is attached to a rigid ring. In surgical valves, the stent is generally 
made with residual flexibility. To have a safe delivery system that poses less risks for the 
vascular tissue, catheter sizes are designed to be as small as possible, this feature usually 
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entails using thinner material for the leaflets, which in turn could be less durable in 
comparison to the thicker bovine pericardium used in many surgical valves (28).  
Increased leaflet mechanical stress has been identified as one of the main 
mechanisms in the pathogenesis of SVD that cause thickened valve leaflet tissues (29). 
These are in accordance with the findings of our finite element modeling results. As 
displayed in Figure 16, the SAPIEN 3 valve has a higher maximum in-plane stress value 
in systole compared to the CE Perimount Magna (16 MPa in comparison to 4.75 MPa) 
even though this high peak is seen in few elements. Moreover, during systole, 38.5% of 
SAPIEN 3 elements had stress values of higher than 400 kPa compared to 20.2% of 
elements in PERIMOUNT Magna, verifying the clinical speculation of higher stress values 
with transcatheter valves. Also, in diastole, 86.7% of the elements in PERIMOUNT Magna 
had a stress of -100 kPa to 100 kPa in comparison to 62.8% of SAPIEN 3 elements in this 
range while over 35% of SAPIEN 3 elements had stress values of over 100 kPa.  
This difference could arise from the thinner leaflets in the SAPIEN 3 valve (0.33 
mm) compared to the 0.5 mm thick surgical valve leaflets. In order to develop delivery 
catheters and sheath sizes with lower profiles, the TAVR leaflets need to be made from 
thinner material, for example the SAPIEN 3 device currently has a 14 F delivery catheter.  
In accordance to these findings, TMVR devices may potentially have lower durability in 
comparison to their surgical counterparts. This is in agreement with the study that Martin 
et al. (30) led, they investigated TAV and SAV leaflet fatigue. To identify the pericardial 
leaflets’ behavior, they built a computational soft tissue fatigue damage model and 
implemented cyclic loading. TAV and SAV leaflets had equal loading conditions and 
identical leaflet tissue properties, but higher stresses, strains, and fatigue damage were 
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witnessed on the TAV leaflets. They concluded that TAV durability could be significantly 
reduced compared to SAVs to about 7.8 years. Abbasi et al. (34) also reports higher stress 
values in TAV leaflets after computational simulation and speculates that the increased 
mechanical stress on the leaflets may clarify why the tissue degeneration is accelerated and 
the long-term durability is reduced.  
The leaflet’s computational model is only accurate if the properties that are 
assigned to it to simulate the bovine and porcine pericardium leaflet behavior are correct. 
There are reported differences in the structure and composition of pericardium leaflets, 
hence, it is necessary to use a three-dimensional anisotropic material model for the fixed 
biological tissue to correctly describe the mechanical properties of the leaflets, as done in 
this work. Furthermore, to correctly identify bioprostheses’ failure mechanisms, it is 
important to inspect bioprosthetic heart valves under dynamic loading conditions. 
      4.1. Thrombosis 
Valve thrombosis is another mechanism of failure that occurs in bioprosthetic 
valves (32) and this study aimed to compare the risk of thrombosis between the intra-
annular and supra-annular designs, ultimately comparing the thrombosis risk to that of a 
surgical mitral valve replacement device. Overall, bioprosthetic valves are regarded as less 
thrombogenic than mechanical valves, in many cases, removing the need for long-term oral 
anti-coagulation therapy. Nevertheless, thromboembolic event risk is still not insignificant, 
especially during the first 3 months post SAVR. The incidence of valve thrombosis 
following SAVR is predicted as ranging from 0.03 events per 100 patient years, and a 
reported 15-year incidence of 0.37% to 26% (39). Another study reported that in the early 
post operation time after surgical bioprosthetic valve replacement, there is an increase in 
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risk of thromboembolic events. Early observational experience estimated the general 
thromboembolic risk to be around 2.3% per year post bioprosthesis implantation, with most 
events happening during the first 90 days. 
The type of anti-coagulation therapy is also important, the Society of Thoracic 
Surgeons Adult Cardiac Surgery National Database stated that after bioprosthetic aortic 
valve replacement, embolic events have a very low rate at 90 days (0.9%), also presenting 
a decreased risk of death and embolic events (relative risk reduction 20% and 48%, 
respectively) in patients that took warfarin as well as aspirin in comparison to the aspirin-
only therapy. There is no evidence of thrombosis risk in bioprosthetic mitral valve 
replacement, but it seems the risk of mitral bioprosthesis thrombosis is higher than what it 
is for bioprosthetic aortic valves (40).  
Moreover, late valve thrombosis is identified as an important factor in bioprosthetic 
valve dysfunction in the long-term. Egbe et al. concluded from an observational study that 
the median time for explanting a surgical valve due to thrombosis is 24 months with 15% 
of cases happening later than 5 years post-op (40).  
In the case of TAVR, a systematic review reported 15 THV thrombosis cases, while 
14 of those were for the Edwards SAPIEN THV, with mean time to diagnosis being 9 ± 7 
months. THV thrombosis seems to be a rare event: the randomized PARTNER trials and 
the TAVR registries did not report any cases of thrombosis. In the PARTNER EU trial, 
just one THV thrombosis case (0.8%) was reported out of the 130 TAVR recipients (31). 
During the clinical evaluation of the potential TMVR designs, the rate of THV thrombosis 
was rather concerning (6% to 8%) at different stages post Tendyne (Abbott Vascular, 
Abbott Park, Illinois), HighLife (HighLife Medical, Irvine, California), and Fortis 
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(Edwards Lifesciences, Irvine, California) device implantation. In the case of the Fortis 
THV program, Edwards Lifesciences had to stop the program because of device thrombosis 
issues in May 2015 (40).  
As mentioned before, blood residence time (BRT) and wall shear stress are 
recognized as factors related to thrombus formation, providing a method of quantifying 
risk of thrombosis in computational simulations. Vahidkhah et al. (41) investigated the 
effect of transcatheter aortic valve geometric confinement on BRT over the TAV leaflets 
and then assessed risk of valve thrombosis post TAVR. To this end, computational models 
of a TAV and a surgical bioprosthesis were created to analyze how geometric confinement 
can affect BRT over the leaflets in cases like ViV or intra-annular positioning of TAVR. 
A one-way fluid-solid interaction method was developed to find the 3D flow fields. 
Randomly distributed particles around the leaflets were analyzed to quantify their residence 
time and compare BRT among the models. At different time points over the cardiac cycle, 
the TAV model had significantly longer BRT over the leaflets. It was concluded that when 
the calcified native valve or failed bioprosthesis creates a  geometric confinement for the 
TAV, BRT increases on the TAV leaflets, potentially indicating that it is a contributing 
factor for valve thrombosis. 
In this context, it has been shown that RT is a way of quantifying fluid stagnation 
in a specific location, helping to give a time frame in the process of thrombus formation 
(33).  In this work, we initially built the groundwork to do this assessment and used steady-
state simulations to verify the feasibility of finding the pressure and velocity field within 
the left ventricle and atrium. Even in this simplified simulation, differences in the regions 
and values of high pressure and velocity can be observed. The main aim is to understand if 
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the position of the valve within the mitral annulus makes a difference in the risk of 
thrombosis and compare that to a surgical valve with the hypothesis that  BRT will be 
significantly higher on the TMV leaflets with supra-annular design compared to intra-
annular design. In addition, increased regions of blood stasis will be observed around the 
supra-annular TMV leaflets in the left atrium. Steady-state results in Figure 23 show higher 
velocity and lower pressure in the main jet region in the intra-annular model in comparison 
with the supra-annular model, potentially indicating less stasis.  However, this will need to 
be verified with a transient model, incorporating the leaflet and valve motion in the model 
and quantifying the value of BRT. The LV motion was obtained in order to build this 
complex CFD model and this is the main part of the future work for this research. 
Furthermore, a finite element analysis can be conducted to determine the influence of the 
leaflet thickness reduction in THVs on stress and strain distribution, and ideally find an  
optimum leaflet thickness that accommodates the needs of the delivery system and has 
similar stress distribution on the leaflets as the surgical valve. 
      4.2. Conclusion 
In summary, in order to find the 3D anisotropic mechanical properties for 
bioprosthetic mitral valves while undergoing physiological loading conditions, an 
optimization procedure was utilized. Two different bioprosthetic heart valves that were 
close in terms of size were studied. After finding the optimized material parameters, an FE 
simulation was run for each valve to visualize the stress distribution and demonstrate leaflet 
deformation. In systole, at the fixed boundary edge for the bioprostheses, most high stress 
regions were witnessed. On the other hand, in diastole, the high stress regions were mainly 
seen in the commissures of the two valves. The results of the stress distribution were related 
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to predicting valve durability and it seems that the transcatheter valve may have lower 
durability due to the high stress regions observed. Computational models of the left side of 
the heart were built and the movement of the left ventricle during a cardiac cycle was 
simulated through finding optimized hyperelastic material properties. Three CFD models 
were built from the left heart model with the SAPIEN 3 valve placed in intra and supra-
annular positions and the PERIMOUNT Magna placed intra-annularly. Steady-state 
simulations were run to demonstrate the feasibility of obtaining the flow field in this 
geometry and show initial differences between these models. Further studies include 
incorporating the movement of the leaflets and the left ventricle into the CFD model to 
quantify blood residence time and quantitatively identify the risk of thrombosis in each of 
these models. Patient-specific cardiac modeling could potentially help to plan procedures 
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